Abstract: Provided is a tire including a tread portion. The tread portion includes two circumferential grooves and three land portions. The three land portions include a crown land portion disposed on a tire equator, and two shoulder land portions including tread contact ends. At least one of the shoulder land portions includes a plurality of main inclined grooves and a plurality of subsidiary inclined grooves. The main inclined grooves have tire-axially inner ends ending in the shoulder land portions and tire-axially outer ends disposed outwardly of the tread contact ends Te in the tire axial direction. The subsidiary inclined grooves have tire-axially inner ends ending in the shoulder land portions and tire-axially outer ends ending in the shoulder land portions.

Abstract: A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

Abstract: The present invention provides a drug for a pathological condition including mitochondria-related disease by a conjugate of a double-membrane organelle DNA sequence recognizing compound and a double-membrane organelle localizable compound. The present invention provides a conjugate in which a double-membrane organelle localizable lipophilic cation is attached to linear PI polyamide that specifically binds to a double-membrane organelle DNA sequence, a linear PI polyamide-TPP conjugate targeting the mitochondrial DNA mutation or polymorphism, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.

Abstract: A first land region is defined between a first main groove and a second main groove extending in a tyre circumferential direction. The first land region is provided with a first oblique groove and a second oblique groove. The first oblique groove extends obliquely with respect to a tyre axial direction from the first main groove to have an end portion terminating within the first land region. The second oblique groove extends obliquely with respect to the tyre axial direction from the second main groove to intersect with a middle groove portion of the first oblique groove and terminate there.

Abstract: A tire includes having a tread portion that has three land portions defined by two crown main grooves that continuously extend in a tire circumferential direction and that are arranged across a tire equator. The three land portions include two shoulder land portions. At least one of the shoulder land portions includes a plurality of main inclined grooves that extend so as to be inclined. At least one of the main inclined grooves has an inner end and an outer end. The main inclined groove has a steeply-inclined portion that extends so as to be inclined from the inner end toward a tread end, and a gently-inclined portion that extends across the tread end from the outer end at an angle, relative to an tire axial direction, which is less than an angle of the steeply-inclined portion relative thereto. A length of the steeply-inclined portion is greater than a length of the gently-inclined portion.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: A blower device includes a motor having an output shaft and a housing; a fan rotationally driven by the motor; and a shroud having a shroud body with a fan installation hole, and a motor mounting part for mounting the motor arranged inside the fan installation hole when viewed in an axial direction of the output shaft. The motor mounting part includes an inner cylinder surrounding a periphery of the motor from a radial outer side of the output shaft; an outer cylinder surrounding the inner cylinder from the radial outer side; and spokes connecting the inner and the outer cylinders. The inner cylinder includes a top wall covering the motor from above while the shroud is fixed. A back end edge of the top wall, which is located on a positive pressure side when the fan is rotated, is located closer to the positive pressure side than the housing.

Abstract: A cooling-fan-apparatus fan shroud includes: a cover wall that closes a space between a heat exchanger and a circumference of a fan; and a passing permitting frame part that is positioned between the fan and an attachment part to a vehicle at an outer side of the cover wall and that allows free passing of traveling air, wherein a reinforcement rib is provided at an opening of the passing permitting frame part, and at least part of the reinforcement rib is a deflection louver that guides the traveling air to a predetermined direction.

Abstract: Provided is a tire including a tread portion. The tread portion includes two circumferential grooves and three land portions. The three land portions include a crown land portion disposed on a tire equator, and two shoulder land portions including tread contact ends. At least one of the shoulder land portions includes a plurality of main inclined grooves and a plurality of subsidiary inclined grooves. The main inclined grooves have tire-axially inner ends ending in the shoulder land portions and tire-axially outer ends disposed outwardly of the tread contact ends Te in the tire axial direction. The subsidiary inclined grooves have tire-axially inner ends ending in the shoulder land portions and tire-axially outer ends ending in the shoulder land portions.

Abstract: A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

Abstract: A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: A blower device includes a motor having an output shaft and a housing; a fan rotationally driven by the motor; and a shroud having a shroud body with a fan installation hole, and a motor mounting part for mounting the motor arranged inside the fan installation hole when viewed in an axial direction of the output shaft. The motor mounting part includes an inner cylinder surrounding a periphery of the motor from a radial outer side of the output shaft; an outer cylinder surrounding the inner cylinder from the radial outer side; and spokes connecting the inner and the outer cylinders. The inner cylinder includes a top wall covering the motor from above while the shroud is fixed. A back end edge of the top wall, which is located on a positive pressure side when the fan is rotated, is located closer to the positive pressure side than the housing.

Abstract: A tire includes having a tread portion that has three land portions defined by two crown main grooves that continuously extend in a tire circumferential direction and that are arranged across a tire equator. The three land portions include two shoulder land portions. At least one of the shoulder land portions includes a plurality of main inclined grooves that extend so as to be inclined. At least one of the main inclined grooves has an inner end and an outer end. The main inclined groove has a steeply-inclined portion that extends so as to be inclined from the inner end toward a tread end, and a gently-inclined portion that extends across the tread end from the outer end at an angle, relative to an tire axial direction, which is less than an angle of the steeply-inclined portion relative thereto. A length of the steeply-inclined portion is greater than a length of the gently-inclined portion.

Abstract: A first land region is defined between a first main groove and a second main groove extending in a tyre circumferential direction. The first land region is provided with a first oblique groove and a second oblique groove. The first oblique groove extends obliquely with respect to a tyre axial direction from the first main groove to have an end portion terminating within the first land region. The second oblique groove extends obliquely with respect to the tyre axial direction from the second main groove to intersect with a middle groove portion of the first oblique groove and terminate there.

Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: An object of the present invention is to provide a novel alkylating agent that specifically binds to an immune checkpoint gene to induce cell death, and has tumor-specific accumulating properties. The present invention provides a conjugate comprising an alkylating agent bonded to a polyamide that specifically binds to a gene encoding an immune checkpoint molecule, an alkylating agent specific for a gene encoding an immune checkpoint molecule, comprising the conjugate, and a pharmaceutical composition comprising the conjugate.